+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Wilson's Disease Treatment Market, by Treatment Medications, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • PDF Icon

    Report

  • 185 Pages
  • June 2022
  • Region: Global
  • Coherent Market Insights Pvt Ltd.
  • ID: 5626519
Wilson’s disease is a genetic disorder caused by the loss of function of the ATP7B copper-binding protein that leads to impaired copper transport and excretion, which results in accumulation of free copper in the bloodstream that results in damage of liver, brain, and other organs. As Wilson’s disease is hard to differentiate from other serious hepatic or neurologic conditions such as jaundice and kidney failure, which results in less number of patient to be diagnosed than the actual prevalence of Wilson’s disease. Wilson’s disease is characterized by the degree of accumulation of free copper in liver and the brain. Whereas, the patients that suffer from Wilson’s disease can either be asymptomatic or can have one or more clinical symptoms which can vary in type and its severity that include liver disease, neurologic manifestations and psychiatric disturbances. The symptoms for Wilson’s disease may include abdominal pain, lack of appetite, fatigue, jaundice, problems with speech, swallowing or physical coordination, and uncontrolled movements or muscle stiffness. Wilson’s disease is suspected in the individuals of age 3 - 60 years, whereas the chance of child inheriting autosomal recessive mutation from both the parent by gene mutation is 25% or one in four ratio.



Wilson’s disease, also known as hepatolenticular degeneration or progressive lenticular degeneration, is a rare genetic disorder caused by copper poisoning in the body. In a healthy body, the liver filters the excess copper and releases it through urine. The liver of a person suffering from Wilson’s disease cannot perform this function. Wilson’s disease is diagnosed by blood tests through abnormalities in liver enzymes, copper levels in the blood, lower levels of ceruloplasmin, a protein that carries copper through the blood, a mutated gene or low blood sugar. Treatments of Wilson’s Disease include oral drugs containing zinc, d-penicillamine, Tetrathiomolybdate, and trientine or syprine.

Market Dynamics


Rising incidence of Wilson’s disease is due to increase in the population worldwide, as Wilson’s disease is a rare genetic disorder which, is expected to favor growth for Wilson’s disease treatment market around the globe. For instance, according to data published by National Library of Medicine, National Institute of Health, in May 2022, high incidence of Wilson’s disease is due to increased rate of consanguineous marriages. Both males and females are equally affected by Wilson’ disease.

Key features of the study:

  • This report provides an in-depth analysis of the global Wilson’s disease treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global wilson’s disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Wilson’s disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Wilson’s disease treatment market

Detailed Segmentation:

Global Wilson’s Disease Treatment Market, By Treatment Type:

  • Medications
  • D-Penicillamine
  • Trientine
  • Zinc
  • Tetrathiomolybdate
  • Others

Global Wilson’s Disease Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Government Bodies

Global Wilson’s Disease Treatment Market, By Region:

  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa

Company Profiles:

  • Valeant Pharmaceuticals International. Inc.
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Noblepharma Co., Ltd.
  • Wilson Therapeutics AB
  • Kadmon Holdings, Inc.
  • Merck & Co.
  • VHB Life Science Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Tsumura & Co.
Frequently Asked Questions about the Global Wilson Disease Treatment Market

What is the estimated value of the Global Wilson Disease Treatment Market?

The Global Wilson Disease Treatment Market was estimated to be valued at $527 Million in 2022.

What is the growth rate of the Global Wilson Disease Treatment Market?

The growth rate of the Global Wilson Disease Treatment Market is 6.2%, with an estimated value of $854.5 Million by 2030.

What is the forecasted size of the Global Wilson Disease Treatment Market?

The Global Wilson Disease Treatment Market is estimated to be worth $854.5 Million by 2030.

Who are the key companies in the Global Wilson Disease Treatment Market?

Key companies in the Global Wilson Disease Treatment Market include Valeant Pharmaceuticals International. Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., VHB Life Science Ltd. and Tsumura & Co..

Table of Contents

1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
  • Publisher Opportunity Map

3. Market Dynamics, Regulations, and Trends Analysis
  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Market Trends
  • New Product Launches
  • Regulatory Scenario
  • PEST Analysis
  • PORTER’s Analysis
  • Key Developments
  • Brand Analysis
  • Strategic Agreement, Merger And Acquisitions

4. Global Wilson’s Disease Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Wilson’s Disease Treatment Market, By Treatment Type, 2017 - 2030, (US$ Million)
  • Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
  • Medications Brand
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • D-Penicillamine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Trientine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Zinc
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Tetrathiomolybdate
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Wilson’s Disease Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
  • Hospital pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Government Distribution Channel
  • Overview
  • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2030, (US$ Million)
  • Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Wilson’s Disease Treatment Market, By Region, 2017 - 2030, (US$ Million)
  • Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018-2030
  • Regional Trends
  • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Formulation, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Formulation, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Formulation, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • UK
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Formulation, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Formulation, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Formulation, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

8. Competitive Landscape
  • Valeant Pharmaceuticals International. Inc.
  • Kadmon Holding, Inc.
  • Merck & Co.
  • VHB Life Science Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Wilson’s Therapeutics AB
  • Noble Pharma Co., Ltd
  • Tsumura & Co.

9. Section
  • Research Methodology
  • About Us

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Valeant Pharmaceuticals International. Inc.
  • Noblepharma Co., Ltd.
  • Wilson Therapeutics AB
  • Kadmon Holdings, Inc.
  • Merck & Co.
  • VHB Life Science Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Tsumura & Co.